JP2014523906A5 - - Google Patents

Download PDF

Info

Publication number
JP2014523906A5
JP2014523906A5 JP2014519502A JP2014519502A JP2014523906A5 JP 2014523906 A5 JP2014523906 A5 JP 2014523906A5 JP 2014519502 A JP2014519502 A JP 2014519502A JP 2014519502 A JP2014519502 A JP 2014519502A JP 2014523906 A5 JP2014523906 A5 JP 2014523906A5
Authority
JP
Japan
Prior art keywords
administered
drug
defensins
agent
human
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2014519502A
Other languages
English (en)
Japanese (ja)
Other versions
JP6219277B2 (ja
JP2014523906A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2012/063137 external-priority patent/WO2013007596A2/en
Publication of JP2014523906A publication Critical patent/JP2014523906A/ja
Publication of JP2014523906A5 publication Critical patent/JP2014523906A5/ja
Application granted granted Critical
Publication of JP6219277B2 publication Critical patent/JP6219277B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2014519502A 2011-07-08 2012-07-05 炎症性腸疾患の経口治療 Active JP6219277B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP11173351 2011-07-08
EP11173351.5 2011-07-08
US201161506437P 2011-07-11 2011-07-11
US61/506,437 2011-07-11
PCT/EP2012/063137 WO2013007596A2 (en) 2011-07-08 2012-07-05 Oral treatment of inflammatory bowel disease

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2017008251A Division JP6251827B2 (ja) 2011-07-08 2017-01-20 炎症性腸疾患の経口治療

Publications (3)

Publication Number Publication Date
JP2014523906A JP2014523906A (ja) 2014-09-18
JP2014523906A5 true JP2014523906A5 (https=) 2015-08-20
JP6219277B2 JP6219277B2 (ja) 2017-10-25

Family

ID=47506622

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014519502A Active JP6219277B2 (ja) 2011-07-08 2012-07-05 炎症性腸疾患の経口治療
JP2017008251A Active JP6251827B2 (ja) 2011-07-08 2017-01-20 炎症性腸疾患の経口治療

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2017008251A Active JP6251827B2 (ja) 2011-07-08 2017-01-20 炎症性腸疾患の経口治療

Country Status (5)

Country Link
US (3) US9217021B2 (https=)
EP (1) EP2729159B1 (https=)
JP (2) JP6219277B2 (https=)
ES (1) ES2637286T3 (https=)
WO (1) WO2013007596A2 (https=)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201170219A1 (ru) 2008-07-18 2011-08-30 Новозимс Эдениум Байотек А/С Лечение воспалительных заболеваний кишечника бета-дефенсинами млекопитающих
US9217021B2 (en) 2011-07-08 2015-12-22 Defensin Therapeutics Aps Oral treatment of inflammatory bowel disease
KR101590452B1 (ko) 2015-05-20 2016-02-02 중앙대학교 산학협력단 펩타이드 defb124를 유효성분으로 포함하는 면역증강 및 암 예방 또는 치료용 약학적 조성물
WO2017027411A1 (en) * 2015-08-07 2017-02-16 The Regents Of The University Of California Compositions and methods for inhibiting pro-inflammatory cytokine gene expression
KR20180121489A (ko) * 2016-01-26 2018-11-07 디펜신 테라퓨틱스 에이피에스 장내 미생물을 조절하는 방법
CA3022497A1 (en) * 2016-04-29 2017-11-02 Defensin Therapeutics Aps Treatment of liver, biliary tract and pancreatic disorders
JP7129912B2 (ja) * 2016-12-07 2022-09-02 株式会社ステリック再生医科学研究所 慢性疾患の治療及び予防用医薬組成物
CN110290799A (zh) 2016-12-13 2019-09-27 防御素治疗学公司 用于治疗肺部炎性病症的方法
RU2020115758A (ru) * 2017-11-10 2021-12-10 Дефенсин Терапьютикс Апс Созревание защитной функции слизистых оболочек и функции кишечника/легких у недоношенного ребенка
EP3713590B1 (en) * 2017-11-24 2025-05-07 Defensin Therapeutics ApS Human beta 2 defensin for use in the prevention and treatment of graft-versus-host-disease
KR102244161B1 (ko) * 2018-08-31 2021-04-26 주식회사 나이벡 다중의 질환 바이오마커의 기능 및 발현을 억제하는 펩타이드의 신규한 용도
WO2020076925A1 (en) 2018-10-09 2020-04-16 Dat Tran Compositions and methods for enhancing systemic deliverability, tolerability, and efficacy of cationic macrocyclic peptides

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
IL99552A0 (en) 1990-09-28 1992-08-18 Ixsys Inc Compositions containing procaryotic cells,a kit for the preparation of vectors useful for the coexpression of two or more dna sequences and methods for the use thereof
DE4343591A1 (de) 1993-12-21 1995-06-22 Evotec Biosystems Gmbh Verfahren zum evolutiven Design und Synthese funktionaler Polymere auf der Basis von Formenelementen und Formencodes
US5605793A (en) 1994-02-17 1997-02-25 Affymax Technologies N.V. Methods for in vitro recombination
DE19824484A1 (de) * 1998-06-02 1999-12-09 Bayer Ag Festkörperreiche Polyurethandispersionen mit hoher Applikationssicherheit
DE19957043A1 (de) 1999-11-26 2001-06-07 Forssmann Wolf Georg Neue Defensine
US7338936B2 (en) 2000-11-28 2008-03-04 House Ear Institute Use of antimicrobial proteins and peptides for the treatment of otitis media and paranasal sinusitis
US20080194481A1 (en) 2001-12-21 2008-08-14 Human Genome Sciences, Inc. Albumin Fusion Proteins
FR2841556B1 (fr) 2002-07-01 2007-07-20 Centre Nat Rech Scient Peptides ayant des proprietes antimicrobiennes et les compositions les contenant notamment pour la conservation des aliments
AU2003288507A1 (en) 2002-12-19 2004-07-14 Yitzchak Hillman Disease treatment via antimicrobial peptide inhibitors
US20070207209A1 (en) 2004-08-27 2007-09-06 Murphy Christopher J Trophic factor combinations for nervous system treatment
GB0514482D0 (en) 2005-07-14 2005-08-17 Ares Trading Sa Protein
WO2007081486A2 (en) 2005-12-15 2007-07-19 Ventria Bioscience Oral administration of defensins to treat intestinal diseases
WO2007087557A2 (en) 2006-01-24 2007-08-02 University Of Maryland Biotechnology Institute Surface-layer protein coated microspheres and uses thereof
WO2009046835A1 (en) 2007-09-11 2009-04-16 Mondobiotech Laboratories Ag Use of goserelin and amylin as therapeutic agents
AR072525A1 (es) 2008-07-18 2010-09-01 Novozymes As Tratamiento de artritis reumatoidea con beta defensinas de mamiferos. uso. metodo.
EA201170219A1 (ru) 2008-07-18 2011-08-30 Новозимс Эдениум Байотек А/С Лечение воспалительных заболеваний кишечника бета-дефенсинами млекопитающих
AP2011005537A0 (en) 2008-07-18 2011-02-28 Novozymes Adenium Biotech As Treatment of inflammatory diseases with mammal beta defensins.
EP2343292B1 (en) 2008-09-10 2014-08-06 Asahi Glass Company, Limited Novel prostaglandin i2 derivative
JP2011121887A (ja) * 2009-12-09 2011-06-23 En Otsuka Pharmaceutical Co Ltd 炎症性腸疾患用アミノ酸組成物
JP4620169B1 (ja) * 2010-01-28 2011-01-26 株式会社三和化学研究所 有機酸重合体を有効成分とするクローン病の予防又は治療剤
US9217021B2 (en) 2011-07-08 2015-12-22 Defensin Therapeutics Aps Oral treatment of inflammatory bowel disease
US20130052213A1 (en) 2011-08-19 2013-02-28 Novozymes A/S Novel immunomodulatory peptide

Similar Documents

Publication Publication Date Title
JP2014523906A5 (https=)
Liang et al. Therapeutic roles of polysaccharides from Dendrobium Officinaleon colitis and its underlying mechanisms
JP2012502113A5 (https=)
Wang et al. Role of crosstalk between glial cells and immune cells in blood-brain barrier damage and protection after acute ischemic stroke
EA201270167A1 (ru) Лекарственная форма глатирамера ацетата с уменьшенным объемом и способы введения
Wang et al. Targeting macrophage autophagy for inflammation resolution and tissue repair in inflammatory bowel disease
US20180353474A1 (en) Method for preventing and/or treating aging-associated cognitive impairment and neuroinflammation
JP2020516615A5 (https=)
JP2013544244A5 (https=)
Burkovskiy et al. Cytokine release in sepsis
Li et al. Neglected mycobiome in HIV infection: Alterations, common fungal diseases and antifungal immunity
JP2011520980A5 (https=)
Sagnak et al. Predictive Value of Urinary Interleukin-8 Cutoff Point for Recurrences After Transurethral Resection Plus Induction Bacillus Calmette-Guérin Treatment in Non–Muscle-Invasive Bladder Tumors
Goh et al. Acute generalised exanthematous pustulosis and toxic epidermal necrolysis induced by carbamazepine
EP3538132B1 (en) Rectal insulin for treatment of inflammatory bowel diseases
Khiong et al. Inhibition of NF-κB pathway as the therapeutic potential of red fruit (Pandanus conoideus Lam.) in the treatment of inflammatory bowel disease
CN102488699B (zh) 芍药苷在制备防治肺纤维化药物中的应用
WO2016150151A1 (zh) 青蒿琥酯在制备治疗中晚期脓毒症药物中的运用
Gao et al. Tripterygium wilfordii polyglycosidium ameliorates pouchitis induced by dextran sulfate sodium in rats
Vaishnavi Management of Recurrent Apthous stomatitis-A Review
Hong et al. Annular leukocytoclastic vasculitis in a patient with ulcerative colitis
Fernandes et al. Paradoxical skin reaction with infliximab treatment
Zhai et al. Inflammatory Dermatosis in HIV/AIDS Patients
ES2541918T3 (es) Composición farmacéutica que combina un agente antiartrítico y un agente inhibidor de interleucina-1, que puede ser utilizado para controlar y tratar osteoartritis y enfermedades relacionadas
Simadibrata et al. Efficacy of Hyaluronic Acid in Radiation Proctitis: A Case Series